Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Antibiotics >  Cephalosporins Drugs >  Ceftizoxime

Ceftizoxime

Basic information Safety Supplier Related

Ceftizoxime Basic information

Product Name:
Ceftizoxime
Synonyms:
  • (6R,7R)-7-[(Z)-2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetylamino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • (6R,7R)-7α-[2-(2-Imino-4-thiazolin-4-yl)-2-[(Z)-methoxyimino]acetylamino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • Ceftizox
  • (7R)-7-[[2-(2-Aminothiazole-4-yl)-2-(methoxyimino)-1-oxoethyl]amino]cepham-3-ene-4-carboxylic acid
  • (7R)-7β-[2-(2-Amino-4-thiazolyl)-2-(methoxyimino)acetylamino]cepham-3-ene-4-carboxylic acid
  • Ceftizoxime (350 mg)I0E2620.999mg/mg(an)
  • Ceftizoxime (350 mg)
  • (6R,7R)-7-[(2Z)-2-(2-aMino-1,3-thiazol-4-yl)-2-(MethoxyiMino)acetaMido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS:
68401-81-0
MF:
C13H13N5O5S2
MW:
383.4
Mol File:
68401-81-0.mol
More
Less

Ceftizoxime Chemical Properties

Melting point:
227° (dec)
Density 
1.89±0.1 g/cm3(Predicted)
pka
pKa 2.1 (Uncertain)
Merck 
14,1951
CAS DataBase Reference
68401-81-0(CAS DataBase Reference)
More
Less

Safety Information

RTECS 
XI0367375
HS Code 
2941906000
Toxicity
LD50 intravenous in rat: 8gm/kg
More
Less

Ceftizoxime Usage And Synthesis

Description

In ceftizoxime, the whole C-3 side chain has been omitted to prevent deactivation by hydrolysis. It rather resembles cefotaxime in its properties; however, not being subject to metabolism, its pharmacokinetic properties are much less complex.

Originator

Eposelin,Fujisawa,Japan,1982

Uses

Antibacterial.

Uses

Ceftizoxime is used for bacterial infections of the lower respiratory tract, infections of the urinary tract, infections of the bones, joints, skin, soft tissues, and abdominal infections. Synonyms of this drug are ceftix and eposerin.

Definition

ChEBI: A parenteral third-generation cephalosporin, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position.

Manufacturing Process

Phosphorus oxychloride (2.0 g) was added at one time at 5°C to 10°C to a suspension of 2-methoxyimino-2-(2-amino-1,3-thiazol-4-yl)acetic acid (syn isomer) (2 g) in dry ethyl acetate (20 ml). After stirring for 20 minutes at 7°C to 10°C, bis(trimethylsilyl)acetamide (0.4 g) was added thereto at the same temperature. After stirring for 10 minutes at 7°C to 10°C, phosphorus oxychloride (2.0 g) was dropwise added thereto at the same temperature. The resulting mixture was stirred for 10 minutes at 7°C to 10°C, and dry dimethylformamide (0.8 g) was dropwise added thereto at the same temperature. The mixture was stirred for 30 minutes at 7°C to 10°C to give a clear solution. On the other hand, trimethylsilylacetamide (7.35 g) was added to a suspension of 7-aminocephalosporanic acid (2.45 g) in dry ethyl acetate (8 ml), after which the mixture was stirred at 40°C to give a clear solution.
To this solution was added at one time the above-obtained ethyl acetate solution at -15°C, and the resulting mixture was stirred for 1 hour at -10°C to -15°C. The reaction mixture was cooled to -30°C, and water (80 ml) was added thereto. The aqueous layer was separated, adjusted to pH 4.5 with sodium bicarbonate and subjected to column chromatography on Diaion HP-20 resin (Mitsubishi Chemical Industries Ltd.) using 25% aqueous solution of isopropyl alcohol as an eluent. The eluate was lyophilized to give 7-[2- methoxyimino-2-(2-amino-1,3-thiazol-4-yl)acetamido]cephalosporanic acid (syn isomer) (1.8 g), MP 227°C (decomp.).

brand name

Cefizox (Astellas).

Therapeutic Function

Antibacterial

Antimicrobial activity

A semisynthetic cephalosporin supplied as the sodium salt. The properties are very similar to those of cefotaxime, but it lacks the acetoxymethyl group at position C-4 and is therefore not subject to deacetylation. Activity against common pathogenic bacteria (Table 13.4) is very similar to that of cefotaxime.
A 500 mg intramuscular injection achieves a plasma concentration of around 14 mg/L. A concentration of 85–90 mg/L is produced 30 min at the end of a 30-min intravenous infusion. The plasma half-life is 1.3–1.9 h. Protein binding is 30%. It is well distributed. In children with meningitis receiving 200–250 mg/kg per day in four equally divided doses for 14–21 days, mean CSF concentrations 2 h after a dose were 6.4 mg/L on day 2 and 3.6 mg/L on day 14.
About 70–90% of the dose is recovered in the urine in the first 24 h, principally by glomerular filtration. Probenecid increases the plasma half-life by about 50%. In patients receiving 1 g intravenously over 30 min, the plasma elimination half-life rose to 35 h when the corrected creatinine clearance was <10 mL/ min. It is partly removed by peritoneal and hemodialysis.
Adverse reactions and clinical use are similar to those of cefotaxime.

Chemical Synthesis

Ceftizoxime, α-O-methyloxime of (6R,7R)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid (32.1.2.64), is synthesized by the scheme described below, which begins with 4-nitrobenzyl ester of 3-hydroxy-7-(2-phenylacetamido)-3-cefem-4-carboxylic acid (32.1.2.57), which is synthesized using a number of methods used to synthesize cefaclor (32.1.2.48). Reducing the C3–C4 double bond in the initial 4-nitrobenzyl ester of 3-hydroxy-7-(2-phenylacetamido)-3-cefem- 4-carboxylic acid (32.1.2.57) with sodium borohydride in methanol, 4-nitrobenzyl ester of 3-hydroxy-7-(2-phenylacetamido)-3-cefam-4-carboxylic acid (32.1.2.58) is obtained, the hydroxyl group in which it is acylated by acetic anhydride in pyridine, forming acetate (32.1.2.59). Reacting this with triethylamine removes a molecule of acetic acid, giving the 4-nitrobenzyl ester of 7-(2-phenylacetamido)-3-cefem-4-carboxylic acid (32.1.2.60). Reacting this with phosphorous pentachloride in pyridine, followed by subsequent methanolysis deacylates the amide fragment of the molecule, giving the 4-nitrobenzyl ester of 7-amino- 3-cefem-4-carboxylic acid (32.1.2.61).
Preliminary silylation of the amino group of this compound with trimethylsilylacetamide and subsequent acylation with 2-(2-formamido-4-thiazolyl)-2-methoxyminoacetic acid chloride synthesized directly in reaction conditions by reacting with phosphorous chloroxide in dimethylformamide gives the 4-nitro-benzyl ester of α-O-methyloxime of 7-[2-(2-formamido-4-thiazolyl)glyoxylamido]-8-oxo-t-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid (32.1.2.62). Reducing this with hydrogen using a palladium on carbon catalyst removes the 4-nitrobenzyl protection from the carboxyl group, forming the acid (32.1.2.63). Finally, hydrolysis of the formamide region of the molecule using hydrogen chloride in methanol gives the desired ceftizoxime (32.1.2.64).

Ceftizoxime Preparation Products And Raw materials

Raw materials

CeftizoximeSupplier

J & K SCIENTIFIC LTD.
Tel
010-82848833- ;010-82848833-
Email
jkinfo@jkchemical.com;market6@jkchemical.com
TCI (Shanghai) Development Co., Ltd.
Tel
021-67121386 / 800-988-0390
Email
Sales-CN@TCIchemicals.com
Energy Chemical
Tel
021-58432009-
Email
sales8178@energy-chemical.com
XiaoGan ShenYuan ChemPharm co,ltd
Tel
0712-2580635- ;0712-2580635
Email
1791901229@qq.com;1791901229@qq.com;
China Langchem Inc.
Tel
0086-21-58956006,021-38701807;021-58950017
Email
sales@langchem.com